Denorex

Quick links to important sections

Denorex

Method of action: Antipsoriatic, Keratolytic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Denorex

What is Denorex?

Denorex is a brand-name medicated shampoo used to manage various scalp conditions characterized by itching, flaking, and irritation. It belongs to a class of topical products designed to treat symptoms associated with dandruff, seborrheic dermatitis, and psoriasis.

Primary Ingredients and Action

Depending on the specific formulation, Denorex typically utilizes one of two primary active ingredients:

  • Coal Tar: This ingredient works by slowing the rapid growth of skin cells on the scalp. It helps reduce the accumulation of scales and decreases inflammation and itching.
  • Salicylic Acid: This is a keratolytic agent that helps soften and remove dead skin cells. It facilitates the shedding of the outer layer of the skin, making it easier to wash away flakes.

Many formulations also include cooling agents like menthol, which provide an immediate soothing sensation to help relieve scalp itch upon application.

Therapeutic Purpose

The product is primarily intended for the symptomatic relief of persistent scalp issues. It is used to:

  • Reduce the visible flaking associated with dandruff.
  • Manage the redness and irritation caused by seborrheic dermatitis.
  • Help alleviate the scaling and discomfort resulting from scalp psoriasis.

Denorex is available over-the-counter and is formulated to address different degrees of scalp irritation, from mild flaking to more severe, chronic conditions.

What side effects are possible with Denorex?

Possible side effects and safety information

Regulatory safety information for topical preparations containing Coal Tar and Salicylic Acid is primarily classified by the System-Organ-Class affected and the severity of the reaction. The most common adverse reactions are generally localized to the application site, classified under Skin and Subcutaneous Tissue Disorders. These expected reactions can include temporary stinging, burning, and mild skin irritation not present before use.

Serious Adverse Reactions and Systemic Risk

Labeling for the active ingredients documents the potential for serious adverse reactions, including the possibility of severe allergic reactions that may involve significant swelling or breathing difficulties. A major safety consideration is the risk of Salicylate Toxicity (Salicylism), which may occur if the Salicylic Acid component is excessively absorbed into the bloodstream. Symptoms associated with this systemic absorption can involve the Nervous System and Gastrointestinal Disorders, potentially presenting as dizziness, tinnitus, or vomiting.

Safety Constraints and Exposure Patterns

Specific safety constraints are mandated in regulatory texts. The preparation should not be applied to infected, raw, or otherwise compromised skin due to the increased risk of systemic absorption of the Salicylic Acid. Population-specific safety notes highlight that pediatric patients, particularly young children, are at greater risk of unwanted systemic effects. Exposure-related patterns include the documentation that photosensitivity (increased sun sensitivity) may persist for up to 72 hours after application and wash-off, and that the development of tar acne is linked to long-term use.

Overdose and Emergency Response

The official overdose profile for Denorex, based on the active ingredients, addresses the risk of Systemic Salicylate Toxicity (Salicylism) following accidental ingestion or excessive topical absorption. Documented manifestations of Salicylism include neurological signs such as tinnitus, severe headache, confusion, and dizziness, alongside gastrointestinal effects like nausea and vomiting.

Severe or life-threatening outcomes can include acute Metabolic Acidosis, seizures, and coma. Children and teenagers with concurrent influenza or chickenpox face a specific documented risk of Reye's syndrome in the context of salicylate exposure.

Immediate medical attention must be sought if symptoms of severe toxicity or acute hypersensitivity, such as difficulty breathing, throat tightness, or collapse, are observed. Regulatory agencies mandate calling a Poison Control Center immediately for any known ingestion.

Management focuses on symptomatic and supportive treatment because no specific antidote is known. Procedures documented for severe toxicity include the administration of activated charcoal and, in critical cases, hemodialysis to enhance elimination. Close patient monitoring of acid-base status is required following significant exposure.

Therapeutic Uses of Denorex

What Denorex Treats: Main Uses and Benefits

Denorex is commonly applied to help manage the recurring symptoms of specific dermatological conditions, including dandruff, seborrheic dermatitis, and scalp psoriasis. The medication is utilized for these symptoms to provide relief that helps patients manage difficult, recurrent episodes. It is considered relevant in settings marked by heightened patient distress and is used to help address symptom clusters that may intensify over time.

The medication is applied in addressing the pronounced symptoms of excessive scaling, flaking, and stubborn scalp buildup. It supports the handling of these manifestations and is used when symptoms create noticeable interference with daily stability. The medication is also used for managing the associated symptoms of scalp itching (pruritus), redness, and general irritation. It is applied in situations requiring symptomatic support and is relevant when symptoms become more disruptive during flare-ups. This supports the management of the overall burden of symptoms and contributes to improved comfort during periods of heightened irritation.

“This application may contribute to the management of visible manifestations and assists with maintaining functional stability when symptoms are more noticeable.”

Key Symptom Focus: Supports the easing of symptoms related to inflammatory or irritative states and scaling.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Denorex?

The eligibility for using this topical preparation (Coal Tar/Salicylic Acid) is defined by official regulatory labeling, which establishes specific contraindications and conditional use requirements.


Absolute Contraindications

Denorex is contraindicated in individuals with a known allergy or hypersensitivity to Coal Tar, Salicylic Acid, or any other ingredient. The product must not be used on skin that is infected, blistered, raw, or oozing.

Crucially, due to the Salicylic Acid content, the medicine is prohibited for use in any child or teenager experiencing flu symptoms or chickenpox because of the potential, rare risk of Reye's syndrome.


Populations Requiring Conditional Use

Certain populations must consult a physician prior to use, as mandated by the regulatory label:

  • Pediatric Patients: Use and dosage in children and infants must be determined by a doctor.
  • Pregnant and Breastfeeding Individuals: Consultation is required before use.
  • Comorbidities: Patients with diabetes or poor blood circulation must seek professional guidance.
  • Extent of Condition: Individuals whose scalp condition covers a large area of the body should consult a doctor.

Adults without these conditions are the approved population for use under standard labeled conditions. Specific data comparing the medicine's use in older adults is officially noted as lacking in regulatory guidance.

What should I know about interactions with other medicines?

Interactions with Other Topical Agents and Substances

The official regulatory profile for this medicated topical preparation is structured around preventing localized additive effects and mitigating the risk of systemic absorption of Salicylic Acid. Co-administration with topical mercury-containing preparations (such as ammoniated mercury ointment) is formally restricted due to the potential for a chemical reaction that may cause skin staining and local irritation.

Concurrent use with other topical peeling agents (including tretinoin, benzoyl peroxide, or sulfur) is also restricted. This constraint prevents pharmacodynamic amplification, which could lead to excessive local irritation, peeling, and dryness. Additionally, the label restricts the use of occlusive dressings or application over large surface areas, as these conditions significantly increase the risk of systemic absorption.


Systemic Interaction Potential and Timing Constraints

Since systemic absorption of Salicylic Acid is possible, the label notes potential interactions with systemic medications that affect salicylate clearance or protein binding. These agents include oral anticoagulants, which may increase bleeding risk, and methotrexate, which may result in increased toxicity from decreased renal clearance. Corticosteroids and Sulfonylureas are also documented as having a potential interaction impact.

A critical timing constraint is the documented interaction with Ultraviolet (UV) Radiation. The Coal Tar component is phototoxic, requiring that the treated area be protected from sunlight and sunlamps for up to 72 hours after application to avoid a severe photosensitive reaction. Use is restricted in individuals with renal or hepatic impairment due to the increased risk of salicylate toxicity from reduced systemic clearance.

Mechanism of Action

Denorex contains two active pharmacological agents, coal tar and salicylic acid, which exert synergistic effects on epidermal cellular and physiological processes.


Regulation of Epidermal Cell Proliferation

Coal tar functions as a cytostatic agent by modulating processes within the cell nucleus. Specifically, it influences the excessive DNA synthesis and proliferation rate of keratinocytes. This intrinsic mechanism mediates a reduction in the hyperactive cellular output of the epidermis.


Keratolytic Action and Corneocyte Detachment

Salicylic acid provides a keratolytic effect by modifying molecular steps that govern the adhesion of corneocytes, the cells comprising the outermost layer of the skin. This modification involves the accelerated breakdown of intercellular cement within the stratum corneum, promoting the detachment and separation of these epidermal cells.


Modulation of Inflammatory Pathway Signaling

Coal tar also influences biological systems where specific mediators dominate. It acts to suppress signaling sequences associated with localized cellular hyperactive states and inflammation. This results in the moderation of pathway signaling patterns that mediate inflammatory responses within the tissue.

Dosage and Administration Information

How to Use Denorex: Official Administration Guidelines

Denorex is a medicated liquid (shampoo) intended for topical administration to the scalp. The dosing regimen is based on a structured application pattern for its active ingredients, which include Salicylic Acid 3% or Coal Tar 1.8%.


Dosing and Frequency

For optimal results, the product should be used at least twice a week or as directed by a healthcare provider. Continued regular use is the required pattern for the sustained delivery of the active ingredient.


Procedural Steps for Application

The label specifies a sequence of actions necessary for proper use:

  1. Preparation: The bottle must be shaken well before dispensing.
  2. Application: Apply the liquid to wet hair, massaging gently into the scalp to work up a lather.
  3. Contact Time: Allow the resulting lather to remain on the scalp for a period of several minutes before rinsing.
  4. Completion: Rinse thoroughly with water and repeat the entire application process.

Administration Context

Feature Guideline
Route of Administration Topical (For external use only)
Age-Group Rules Use in children must be determined by a doctor.
Preparation Shake well before use.

These instructions define the non-cosmetic, standardized procedure for administering the medicated shampoo.

Recent Clinical Evidence

Research evidence / Overview of studies for Denorex

The research base for Denorex, which contains the active ingredients Coal Tar and Salicylic Acid, is founded on clinical evaluation that supports its classification as an Over-the-Counter (OTC) preparation. This evidence structure, summarized by the U.S. Food and Drug Administration (FDA) in the OTC Monograph M032, describes what types of studies exist and the way researchers explored how symptoms change over time in specific populations.

Evidence for Use in Scaling and Flaking (Dandruff)

Research exploring conditions characterized by flaking, scaling, and itching of the scalp mainly consists of short-term Randomized Controlled Trials (RCTs) and controlled studies. These trials were applied in studies examining patient-reported experiences among adults whose condition presented with cycles of stability and flare-ups. The short-term studies reported measurements of changes in the quantity of visible scalp scaling that were observed, and documented patterns regarding the reporting of scalp itching levels by participants over the treatment period. Regulatory scientific reviews summarized the research related to the symptomatic management of these conditions.

Evidence for Seborrheic Dermatitis of the Scalp

For seborrheic dermatitis, the research includes controlled clinical trials and evidence summaries that led to the ingredient's regulatory acceptance. These studies were structured to evaluate clinical scaling and crusting on the scalp, measures of redness (erythema), and subjective reports of pruritus among adults with the condition. Trials monitored measured changes in the level of scaling and crusting severity observed during the study period, as assessed by investigators.

Evidence for Managing Scalp Psoriasis

The research examining the use of this combination for scalp psoriasis includes short- to medium-term comparative trials and evidence synthesis used in clinical practice guidelines. Studies were relevant in trials assessing short-term symptom patterns, monitoring the reduction of thick scale and changes in the Psoriasis Area Severity Index (PASI) score. Clinical studies reported that measurable reduction of hyperkeratotic scale thickness was observed in the studied population.

Long-Term Studies and Follow-Up Data

Evidence is limited regarding the long-term use and durability of effect for the active ingredients in this preparation. The majority of research that contributed to the regulatory classification focuses on short-term changes observed over defined time intervals. Long-term effects are not fully established, and there is limited information for long-term outcomes or the patterns of recurrence following extended periods of use. Studies focusing on long-term consistency of findings or prophylactic use are less prevalent in the body of evidence.

Key Studies & References Salicylic Acid (Topical) – MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Denorex (FAQ)


Q: Can Denorex be used to treat skin flaking or irritation on other parts of the body?

The official product documentation indicates that the preparation is approved for topical use on the scalp. Regulatory warnings advise that if a person's condition covers a large area of the body, professional consultation is mentioned as a prerequisite for use.


Q: Is there any official information about using Denorex on children or young adolescents?

According to official label guidelines, use in children must always be determined by a doctor. Use in children or teenagers with flu-like symptoms or chickenpox is specifically noted due to the potential risk of Reye's syndrome.


Q: Are there special considerations for using Denorex in elderly populations?

Regulatory guidance officially states a lack of specific comparative data concerning the use of the medicine in older adults versus other age groups. Official guidance suggests that consultation may be appropriate before use in this population.


Q: Is it possible for the scalp condition to worsen when first starting to use Denorex?

Official labeling contains specific stop-use advice regarding changes in condition. Labeling details that the product should be discontinued and professional consultation sought if the condition worsens or does not improve after regular use.


Q: Does the official information address the use of Denorex for conditions beyond dandruff and seborrheic dermatitis?

Yes, regulatory labeling lists the product's purpose as an effective aid for symptoms associated with psoriasis of the scalp. It is intended to help control the associated flaking, scaling, and itching linked to these chronic conditions.


Q: How is the action of Denorex different from non-medicated shampoos for scalp flaking?

Denorex is classified as a medicated topical agent, providing therapeutic action rather than just cosmetic cleansing. The active ingredients exert a cytostatic effect (slowing down skin cell production) and a keratolytic effect (promoting scale shedding), which is distinct from the action of non-medicated shampoos.


Q: What official guidance exists regarding Denorex causing discoloration or staining of lighter hair colors?

Official regulatory documents indicate that the active ingredient Coal Tar may cause temporary discoloration or staining. The label also notes a separate risk of staining when the product is used concurrently with topical mercury-containing preparations.


Q: Can Denorex be used if someone is simultaneously using a prescription topical medication on their scalp?

The label restricts co-administration with other topical peeling agents (such as tretinoin or benzoyl peroxide) to prevent excessive local irritation. Official guidance notes that use with other prescription topical agents may necessitate consultation.


Q: What is the main difference between the Salicylic Acid and Coal Tar formulas of Denorex in terms of how they work?

The two active ingredients have distinct actions: Coal Tar primarily functions as a cytostatic agent that slows the rapid growth of skin cells, while Salicylic Acid provides a keratolytic effect that breaks down the cement holding skin scales together, promoting their removal.


Q: Does official information suggest using Denorex as a preventative measure after symptoms clear up?

Yes, the official labeling for the product explicitly states that its purpose is to help reduce and prevent recurrence of symptoms associated with dandruff, seborrheic dermatitis, and psoriasis.


Q: What is the difference in active ingredients between Denorex and other popular medicated shampoos like Neutrogena T/Gel or Nizoral?

Denorex typically contains Coal Tar and/or Salicylic Acid as its active ingredients. Other commonly referenced medicated shampoos may contain different active ingredients, such as Ketoconazole, Pyrithione Zinc, or other formulations of Coal Tar.


Q: Are there official warnings about the flammability of any Denorex ingredients?

Official warnings advise that certain product formulations are flammable and must be kept away from heat and open flame. Official warnings advise that the product must be kept away from open flame, which includes avoiding use while smoking.


Q: Can Denorex be alternated with a regular, non-medicated shampoo?

Official guidance indicates that users may wash their hair with a regular shampoo between applications of the medicated product, if they wish. Guidance notes that the medicated product's specific frequency of use is intended to be maintained.


Q: What research themes are commonly associated with the active ingredients in Denorex?

Research themes associated with the active ingredients focus on the antiproliferative and cytostatic effects of Coal Tar, which slow cell turnover, and the keratolytic properties of Salicylic Acid, which aid in the removal of scale.


Q: What are the signs that a user should stop using Denorex and seek medical consultation?

Label information outlines conditions under which the product should be discontinued, such as when the condition worsens or if severe burning, stinging, peeling, dryness, or irritation occurs. Immediate medical help is noted as appropriate for signs of a severe allergic reaction.


Q: Is there a version of Denorex that does not contain a conditioner?

The product is sold in various formulations, which include versions designated as a Shampoo + Conditioner combination, as well as versions without the conditioner designation.


Q: What is the maximum period of time for continuous use of Denorex before a consultation is recommended?

Regulatory warnings generally advise against using the product for prolonged periods without consulting a doctor. This constraint reflects limitations in data concerning long-term use.

How should Denorex be stored and disposed of?

How to Store and Dispose of Denorex?

This section outlines the official, mandatory requirements for the storage and disposal of this medicated topical liquid, as defined by government regulatory documents.

Official Storage and Handling

The product must be stored at controlled room temperature, maintaining a range between 68 F and 77 F ( mathbf20 C to mathbf25 C). It is mandatory to keep the container tightly closed when not in use. The topical liquid must be protected from environmental extremes: Do not freeze and avoid storage in areas with high heat, moisture, or direct light.

Child Safety Requirement: Denorex must be kept out of the sight and reach of children.

Disposal Requirements

Expired or unused portions of the medication must be properly discarded and should not be kept. Regulatory instructions prohibit flushing the medication down the toilet or pouring it into a drain. For specific, local disposal guidance, users must consult a pharmacist or local waste disposal company.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Denorex found in:

A-Z Index: